Picture of Cognition Therapeutics logo

CGTX — Cognition Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Cognition Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview

* Cognition Therapeutics Inc  CGTX.OQ   CGTX.O  is expected
to show no change in quarterly revenue when it reports 
results on August 8. 
    * 
    * ​Refinitiv's mean analyst estimate for Cognition
Therapeutics
Inc is for a loss of 19 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cognition
Therapeutics Inc is $8​, above​ its last closing price of $1.77.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.18       -0.18      -0.21     Missed  -19.8
 Dec. 31 2023  -0.05       -0.22      -0.20     Beat    10.9
 Sep. 30 2022  -0.34       -0.38      -0.29     Beat    24.5​
 Jun. 30 2022  -0.29       -0.32      -0.25     Beat    22.2
 ​​Mar.        -0.29       -0.29      -0.17     Beat    40.7
 31 2022                                                
 Dec. 31 2021  -0.17       -0.26      -11.74    Missed  -4,424
                                                        .1​
 Sep. 30 2021  -0.57       -0.57      -8.12     Missed  -1,324
                                                        .6
 This summary was machine generated August 4 at 18:35 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Cognition Therapeutics

See all news